May 1, 2024, 8:47 AM
May 1, 2024, 6:07 AM
GSK boosts profit forecast on strong shingles vaccine sales
- GSK raises its profit outlook amid robust sales of shingles vaccines.
- Annual core operating profit growth is expected to be between 9-11%, up from the previous forecast of 7-10%.
- CEO Emma Walmsley's strategy focusing on vaccines and infectious diseases seems to be paying off.
Opinions
You've reached the end